These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21684017)

  • 1. Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation.
    Matza LS; Phillips GA; Revicki DA; Ascher-Svanum H; Kaiser D; Stauffer V; Shorr JM; Kinon BJ
    Psychiatry Res; 2011 Oct; 189(3):463-8. PubMed ID: 21684017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.
    Faries D; Ascher-Svanum H; Phillips G; Nyhuis AW; Sugihara T; Stauffer V; Kinon BJ
    BMC Med Res Methodol; 2012 Sep; 12():142. PubMed ID: 22974273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.
    Matza LS; Phillips GA; Revicki DA; Ascher-Svanum H; Malley KG; Palsgrove AC; Faries DE; Stauffer V; Kinon BJ; George Awad A; Keefe RS; Naber D
    Psychiatry Res; 2012 Dec; 200(2-3):835-42. PubMed ID: 22841345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
    Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
    Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation.
    Brown ES; Nejtek VA; Perantie DC; Rajan Thomas N; Rush AJ
    J Clin Psychopharmacol; 2003 Aug; 23(4):384-8. PubMed ID: 12920415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.
    Matza LS; Phillips GA; Revicki DA; Ascher-Svanum H; Malley KG; Palsgrove AC; Faries DE; Stauffer V; Kinon BJ; Awad AG; Keefe RS; Naber D
    Patient Prefer Adherence; 2012; 6():521-32. PubMed ID: 22879738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mood-stabilizer-maintained, remitted bipolar patients: taper and discontinuation of adjunctive antipsychotic medication.
    Saksa JR; Baker CB; Woods SW
    Gen Hosp Psychiatry; 2004; 26(3):233-6. PubMed ID: 15121352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics.
    Lawlor BA
    J Clin Psychiatry; 2004; 65 Suppl 11():5-10. PubMed ID: 15264965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of second-generation antipsychotic discontinuation in first-episode psychosis.
    Miller BJ
    J Psychiatr Pract; 2008 Sep; 14(5):289-300. PubMed ID: 18832960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of clinician awareness of nonadherence using a new structured rating scale.
    Clayton CD; Veach J; Macfadden W; Haskins J; Docherty JP; Lindenmayer JP
    J Psychiatr Pract; 2010 May; 16(3):164-9. PubMed ID: 20485104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 4-Point ordinal Alliance Self-report: a self-report questionnaire for assessing therapeutic relationships in routine mental health.
    Misdrahi D; Verdoux H; Lançon C; Bayle F
    Compr Psychiatry; 2009; 50(2):181-5. PubMed ID: 19216896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
    Kasper S
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.